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Abstract
Introduction: The purpose of this study was to correlate the level of anabolic and catabolic biomarkers in synovial
fluid (SF) from patients with rheumatoid arthritis (RA), patients with osteoarthritis (OA) and asymptomatic organ
donors.
Methods: SF was collected from the knees of 45 OA, 22 RA patients and 20 asymptomatic organ donors. Eight
biomarkers were selected and analyzed by using an enzyme-linked immunosorbent assay: interleukin (IL)-1, IL-6, IL-
8 and IL-11; leukemia-inhibitory factor (LIF); cartilage oligomeric protein (COMP); osteocalcin; and osteogenic
protein 1 (OP-1). Data are expressed as medians (interquartile ranges). The effects of sex and disease activity were
assessed on the basis of the Western Ontario and McMaster Universities index score for patients with OA and on
the basis of white blood cell count, erythrocyte sedimentation rate and C-reactive protein level for patients with
RA.
Results: The mean ages (± SD) of the patients were as follows: 53 ± 9 years for patients with OA, 54 ± 11 years
for patients with RA and 52 ± 7 years for asymptomatic organ donors. No effect of participants’ sex was identified.
In the SF of patients with RA, four of five cytokines were higher than those in the SF of patients with OA and
those of asymptomatic organ donors. The most significant differences were found for IL-6 and IL-8, where IL-6
concentration in SF of patients with RA was almost threefold higher than that in patients with OA and fourfold
higher than that in asymptomatic donor controls: 354.7 pg/ml (1,851.6) vs. 119.4 pg/ml (193.2) vs. 86.97 pg/ml
(82.0) (P < 0.05 and P < 0.05, respectively). IL-8 concentrations were higher in SF of patients with RA than that in
patients with OA as well as that in asymptomatic donor controls: 583.6 pg/ml (1,086.4) vs. 429 pg/ml (87.3) vs. 451
pg/ml (170.1) (P < 0.05 and P < 0.05, respectively). No differences were found for IL-11 in the SF of patients with
RA and that of patients with OA, while a 1.4-fold difference was detected in the SF of patients with OA and that of
asymptomatic donor controls: 296.2 pg/ml (257.2) vs. 211.6 pg/ml (40.8) (P < 0.05). IL-1 concentrations were the
highest in the SF of RA patients (9.26 pg/ml (11.1)); in the SF of asymptomatic donors, it was significantly higher
than that in patients with OA (9.083 pg/ml (1.6) vs. 7.76 pg/ml (2.6); P < 0.05). Conversely, asymptomatic donor
control samples had the highest LIF concentrations: 228.5 pg/ml (131.6) vs. 128.4 pg/ml (222.7) in the SF of
patients with RA vs. 107.5 pg/ml (136.9) in the SF of patients with OA (P < 0.05). OP-1 concentrations were twofold
higher in the SF of patients with RA than those in patients with OA and threefold higher than those in
asymptomatic donor control samples (167.1 ng/ml (194.8) vs. 81.79 ng/ml (116.0) vs. 54.49 ng/ml (29.3),
respectively; P < 0.05). The differences in COMP and osteocalcin were indistinguishable between the groups, as
were the differences between active and inactive OA and RA.
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Conclusions: Activation of selected biomarkers corresponds to the mechanisms that drive each disease. IL-11, LIF
and OP-1 may be viewed as a cluster of biomarkers significant for OA; while profiling of IL-1, IL-6, IL-8, LIF and OP-
1 may be more significant in RA. Larger, better-defined patient cohorts are necessary to develop a biomarker
algorithm for prognostic use.
Introduction
Synovial fluid (SF) biomarker measurement has begun
to provide useful clinical information. It is well under-
stood that SF plays an important role in the lubrication
and nutrition of the articular joint and in the metabo-
lism of cartilage and other connective tissues within the
joint. Biomarkers in SF can be categorized as anabolic
or catabolic. Understanding the relationship between
catabolic and anabolic markers and their changes during
the onset of joint diseases will help to identify the key
biomarkers of diagnostic and/or prognostic value. The
focus of the current study was on proinflammatory
mediators, catabolic cytokines (interleukin (IL)-1, IL-6,
IL-8 and IL-11) and local anabolic markers of cartilage
and bone metabolism (leukemia-inhibitory factor (LIF),
cartilage oligomeric protein (COMP), osteocalcin and
osteogenic protein 1 (OP-1), also called bone morphoge-
netic protein 7 (BMP-7)) that are involved in critical
biological processes, including cell growth and activa-
tion, inflammation, immunity and differentiation. Several
cytokines, such as IL-1, IL-6 and IL-8, have been found
in SF of patients with rheumatoid arthritis (RA). The
best understood is IL-1, which appears to be critical in
the susceptibility to and progression of osteoarthritis
(OA) and which has been shown to contribute to the
induction of proinflammatory mediators (IL-6 and IL-8),
proteolytic enzymes, nitric oxide, prostaglandins and
other mediators and effectors of tissue inflammation
and destruction [1-3]. IL-1 concentrations have been
shown to be elevated in animal models of OA [4], while
the efficacy of IL-1 inhibitors has been tested in OA
patients [5]. In addition, a variety of other cytokines
may be important in OA pathophysiology. For example,
IL-6 has been associated with OA independent of
patient age or weight [6]. In contrast, the potential of
IL-8 and IL-11 as biomarkers for OA or RA has been
studied less. IL-8 is produced excessively by fibroblasts,
macrophages and neutrophils in pathological conditions
[6], while IL-11 is one of the anti-inflammatory cyto-
kines. An imbalance between proinflammatory and anti-
inflammatory cytokines may result in the development
of OA [7]. LIF is a glycoprotein that was originally
defined by its ability to induce the terminal differentia-
tion of murine M1 myeloid leukemia cells, resulting in
the inhibition of their growth. LIF plays an important
role in the induction of acute phase protein synthesis, in
the regulation of both bone formation and bone
resorption and in the degradation of proteoglycans. It
has been detected at high concentrations in SF of
patients with RA [8]. Another biomarker of interest is
COMP, a member of the thrombospondin family of
extracellular proteins, which is abundantly expressed in
human cartilage. COMP has been extensively evaluated
as a biomarker of joint tissue turnover in animals and
humans, where its concentration in the SF or serum
appears to reflect OA severity [9,10].
Prior studies have shown that OP-1 has unique ana-
bolic and anticatabolic activity [11]. OP-1 has been
detected in normal human SF as well as in SF of OA
and RA patients [9]. Furthermore, in cartilage, there is a
strong negative correlation between the concentrations
of OP-1 and those of the IL-6 family of chemokines (IL-
8, IL-11 and LIF) [12], findings which influenced the
choice of biomarkers for evaluation in the current study.
We hypothesize that the activation of SF biomarkers
in OA and RA might be dependent on the mechanism
that drives each disease and that OA and RA might be
characterized by a distinct panel of catabolic and ana-
bolic markers of inflammation and cartilage matrix
metabolism. Thus, the objective of our present study
was to identify the concentrations of selected biomar-
kers in SF in samples taken from patients with RA or
OA as well as from asymptomatic organ donors and to
correlate these values with pathogenesis and disease
activity. The novelty of this study is in the use of SF
from asymptomatic human organ donors. The rationale
for using selected markers was based on previous stu-
dies in human cartilage and the correlation analysis
between markers of catabolism and anabolism for each
disease.
Materials and methods
Study design
This study was approved by the institutional review
board for human investigations at Rush University Med-
ical Center. After securing informed consent from the
participants, SF was obtained from 45 OA patients and
22 age-matched RA patients seen in the outpatient
offices of the Rush University Section of Rheumatology
who were undergoing diagnostic or therapeutic arthro-
centesis as part of their evaluation and therapy. The
patient cohort covered a broad spectrum of age and dis-
ease severity (both RA and OA), and all participants
from many racial and ethnic backgrounds were
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recruited. Specific eligibility criteria are described below.
SF samples were also obtained through the Gift of Hope
Organ & Tissue Donor Network (Elmhurst, IL, USA)
within 24 hours of death from 20 asymptomatic organ
donors with no documented history of joint disease.
The causes of death were cardiopulmonary arrest (n =
9), myocardial infarction (n = 5), liver failure (n = 1),
gunshot wound (n = 1), suicide (n = 1), seizure (n = 1),
intracranial bleeding (n = 1) and gastrointestinal bleed-
ing (n = 1).
Inclusion criteria for OA and RA participants
Inclusion criteria for recruitment into the study were age
≥21 years for all participants. Patients with RA had to ful-
fill the American College of Rheumatology (ACR) criteria
for the diagnosis of RA [13]. Patients with OA had to ful-
fill the ACR criteria for the diagnosis of OA [14].
Exclusion criteria
Patients with concurrent diagnoses of OA and RA and
those with rheumatological disorders other than OA or
RA that could influence their joint symptoms or inflam-
mation were excluded to ensure better-defined experi-
mental groups. Patients for whom arthrocentesis was
not possible, or, when it was performed, did not yield a
sufficient volume of SF were excluded. Patients who
were unable or unwilling to provide informed consent
for the study or for arthrocentesis and patients who
were unable to read or understand the questionnaires
were also excluded.
Study protocol
Patients were screened for eligibility and provided their
informed consent as described above. OA participants
were evaluated on the basis of Western Ontario and
McMaster Universities (WOMAC) index score to assess
their symptoms and disease activity. Standard weight-
bearing radiographs of the knees (standing anteroposter-
ior and lateral views) were obtained from OA and RA
patients. Radiographic OA was defined as the presence
of Kellgren-Lawrence (K-L) grade ≥2 [15]. SF obtained
from the arthrocentesis of the symptomatic knee was
immediately transferred to our research laboratory and
stored at -80°C. Participants’ medical records, physical
histories and laboratory data were reviewed by the study
physician. Complete blood count, complete metabolic
profile, C-reactive protein (CRP) level and erythrocyte
sedimentation rate (ESR) were obtained for each partici-
pant. For RA subjects, rheumatoid factor (RF) was also
obtained.
Biomarker analysis
SF from patients and organ donors was evaluated for IL-
1, IL-6, IL-8, IL-11, LIF, COMP and osteocalcin by
using commercially available enzyme-linked immunosor-
bent assay (ELISA) kits for each biomarker (R&D Sys-
tems, Inc., Minneapolis, MN, USA). The OP-1 assay was
performed by using the ELISA method developed in our
laboratory as previously described [16]. The data are
presented in Figure 1 as median scatterplots, where each
point represents an average of three measurements.
Statistical analysis
All measurements were carried out in triplicate. All data
were entered into a password-protected computer data-
base. A c2 test or Student’s t-test were performed for
the OA, RA and asymptomatic organ donor groups to
compare baseline demographics as well as clinical and
laboratory data. Kruskal-Wallis and unpaired two tailed
Mann Whitney tests were used to compare the concen-
trations of biomarkers in SF samples between the three
experimental groups: OA vs. RA vs. donor. Data are
presented as median (interquartile range) values. Spear-
man’s correlation coefficient was used to correlate the
concentrations of biomarkers against the appropriate
laboratory parameters (for example, K-L grade,
WOMAC index score, WBC count), and statistical sig-
nificance was determined using the Bonferroni correc-
tion for multiple comparisons. Graphs were generated
in Prism 3.0 software (GraphPad Software, La Jolla, CA,
USA). P ≤ 0.05 was considered statistically significant in
two-tailed tests. More than 80% power was estimated to
detect a 1.5-fold difference in various biomarker concen-
trations for the given sample size.
Results
Demographics of the sample population
SF from 45 patients diagnosed with OA (six males and
thirty-nine females; mean age (± SD), 53 ± 9 years) and
22 RA patients (five males and seventeen females; mean
age (± SD), 54 ± 11 years) were entered into the study.
Twenty asymptomatic organ donors (five males and fif-
teen females; mean age (± SD), 52 ± 7 years) were also
included. This study comprised age-matched population
groups, and no sex differences were detected regarding
the level of selected biomarkers within each cohort. The
detailed demographics and baseline characteristics of the
study participants are outlined in Table 1.
SF IL-1 concentrations
The concentrations of IL-1 differed significantly between
the RA and OA groups (9.26 (11.1) pg/ml vs. 7.76 (2.6)
pg/ml; P < 0.05), and between the OA and asymptomatic
organ donor groups (7.76 (2.6) pg/ml vs. 9.08 (1.6) pg/ml;
P < 0.05) (values reported are medians (interquartile
ranges)). The RA and asymptomatic organ donor
groups were not significantly different (P = 0.93). In con-
trast to the IL-6, IL-8 and IL-11 concentrations, IL-1
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concentrations were lower in the OA SF samples than in
the asymptomatic donor samples (Figure 1A and Table 2).
SF IL-6 concentrations
SF IL-6 concentrations were significantly higher in RA
patients than in OA patients or asymptomatic organ
donors. In RA SF, IL-6 concentrations (354.7 (1,851.6)
pg/ml) were threefold higher than in the OA samples
(119.4 (193.2) pg/ml; P < 0.05), and they were fourfold
higher than in the asymptomatic organ donor samples
(86.97 (82.0) pg/ml; P < 0.05). Surprisingly, there was no
statistically significant difference in the IL-6 concentra-
tions between the OA and asymptomatic organ donor
groups (Figure 1B and Table 2).
SF IL-8 concentrations
SF concentrations of IL-8 were significantly higher in
RA patients (583.6 (1,086.4) pg/ml) than in OA patients
(429 (87.3) pg/ml; P < 0.05) and in the asymptomatic
organ donor population (451 (170.7) pg/ml; P < 0.05).
As with IL-6, there was no statistically significant differ-
ence in the IL-8 concentrations between the OA and
asymptomatic organ donor samples (Table 2).
SF IL-11 concentrations
No significant differences were found in the concentra-
tions of IL-11 between RA and OA SF samples (217.5
(178) pg/ml vs. 296.2 (257.2) pg/ml; P = 0.239). How-
ever, OA IL-11 concentrations were higher than those
in the asymptomatic organ donor samples (296.2 (257.2)
pg/ml vs. 211.6 (40.8) pg/ml; P < 0.05); (Table 2).
Figure 1 ELISA data for IL-1, IL-6, OP-1, and LIF measured in SF collected from patients with OA or RA and from asymptomatic organ
donors. Quantitative ELISA data for (A) IL-1, (B) IL-6, (C) OP-1 and (D) LIF measured in synovial fluid collected from the patients with RA or OA
or from asymptomatic organ donors. The data are presented as median scatterplots, where each point represents an average of three
measurements.
Table 1 Demographics and baseline characteristics of
patients with OA or RA and of asymptomatic organ
donorsa
Patient
demographics
OA (n =
45)
RA (n = 22) Donors (n =
20)
Mean age, yr (±SD) 53 ± 9 54 ± 11 52 ± 7
Sex, M/F 6/39 5/17 5/15
WOMAC score 95 to
1,828
NA NA
ESR, mm/hour NA 10 elevated, 12
normal
NA
X-ray (K-L grade) 2-4 NA NA
RF, IU NA All positive NA
SF, WBC/μL <2,000 7,000 to 25,000 <2,000
aOA, osteoarthritis; RA, rheumatoid arthritis; Donors, asymptomatic organ
donor; ESR, erythrocyte sedimentation rate; WOMAC, Western Ontario and
McMaster Universities (WOMAC) index; K-L grade, Kellgren-Lawrence grade;
RF, rheumatoid factor; IU, international units; SF WBC, synovial fluid white
blood cell count; NA, not applicable. The ages of patients and donors are
mean age at study entry ± SD.
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SF OP-1 concentrations
Concentrations of OP-1 measured in SF in this study were
comparable to those previously described [9]. In the asymp-
tomatic organ donor samples (54.49 (29.3) ng/ml), the con-
centrations of OP-1 were about threefold lower than those
in the RA samples (167.1 (194.8) ng/ml; P < 0.05) and
almost twofold lower than those in the OA samples (81.79
(116.0) ng/ml; P < 0.05) (Figure 1C). Moreover, as expected,
the RA group had higher SF OP-1 concentrations than the
OA group (twofold difference; P < 0.05) (Table 2).
SF LIF concentrations
Contrary to other biomarkers measured in this study, the
concentrations of LIF were significantly higher in the asymp-
tomatic organ donor group (228.5 (131.6) pg/ml) than those
detected in the OA group (107.5 (136.9) pg/ml; P < 0.05),
though compared to the RA group, these concentrations
were not significantly different (128.4 (222.7) pg/ml; P =
0.14). There was no significant difference between the RA
and OA groups as well (P = 0.199) (Figure 1D and Table 2).
SF osteocalcin concentrations
Osteocalcin concentrations were comparable in all three
experimental groups: 2.58 (6.6) ng/ml for asymptomatic
organ donor samples, 2.52 (4.9) ng/ml for the OA group
and 1.99 (3.9) ng/ml for the RA group (Table 2).
SF COMP concentrations
As with osteocalcin, concentrations of COMP were also
indistinguishable between the three experimental
groups: 413.2 (339.9) U/L in the asymptomatic organ
donor group, 490.2 (207.5) U/L in the OA group and
507.3 (352.9) U/L in the RA group (Table 2).
Correlation analysis of the biomarker concentrations
identified in RA samples
Strong positive correlations were seen between IL-6 and
IL-8 (Spearman’s r = 0.86, P < 0.001), IL-1 and OP-1
(Spearman’s r = 0.58, P = 0.003) and LIF and osteocal-
cin (Spearman’s r = 0.59, P = 0.002) (Table 3). The SF
WBC count positively correlated with IL-6, IL-8 and LIF
(Spearman’s r = 0.70, P < 0.001; Spearman’s r = 0.57, P
= 0.042; and Spearman’s r = 0.52, P = 0.032, respec-
tively) (Table 3). Only the IL-6 and IL-8 correlations
remained statistically significant after applying the Bon-
ferroni correction for multiple comparisons. No signifi-
cant differences were observed in the concentrations of
studied biomarkers between the patients with positive or
negative RF.
Correlation analysis of the biomarker concentrations
identified in OA samples
In contrast to a positive correlation between the IL-6 and
IL-8 concentrations in RA patients (Table 3), in OA sam-
ples (Table 4) IL-6 and IL-8 correlated negatively (Spear-
man’s r = -0.37, P = 0.001). IL-6 also strongly correlated
with IL-11 and LIF (Spearman’s r = 0.54, P < 0.001; and
Spearman’s r = 0.72, P < 0.001, respectively) and moder-
ately correlated with osteocalcin (Spearman’s r = 0.45, P
= 0.001) (Table 4). There was also a strong negative cor-
relation between the SF LIF concentrations and the IL-1
as well as IL-8 concentrations (IL-1: Spearman’s r =
-0.52, P = 0.0001; IL-8: Spearman’s r = -0.04, P = 0.004)
(Table 4). In contrast, LIF concentrations positively cor-
related with the concentrations of IL-6, IL-11 and osteo-
calcin (Spearman’s r = 0.72, P < 0.001; Spearman’s r =
0.43, P = 0.002; and Spearman’s r = 0.50, P = 0.0003,
respectively) (Table 4). IL-1 strongly correlated with IL-8
(Spearman’s r = 0.62, P < 0.001) and showed moderate
negative correlations with IL-6 and osteocalcin (Spear-
man’s r = -0.33, P = 0.186; and Spearman’s r = -0.034,
P = 0.02) (Table 4). IL-8 and osteocalcin showed a mod-
erate negative correlation (Spearman’s r = -0.44, P =
0.001). COMP and OP-1 did not show any correlation
with other biomarkers (Table 4). After the Bonferroni
correction for multiple comparisons was applied, the
Table 2 Synovial fluid concentrations of the biological markers in patients with OA or RA and in asymptomatic organ
donorsa
P values
Marker Donor (n = 20) OA (n = 45) RA (n = 22) OA vs. donor RA vs. donor OA vs. RA
IL-6, pg/mL 86.97 (82.0) 119.4 (193.2) 354.7 (1851.6) 0.4 0.0011 0.0026
IL-8, pg/mL 451 (170.7) 429 (87.3) 583.6 (1086.4) 0.0809 0.016 <0.0001
IL-11, pg/mL 211.6 (40.8) 296.2 (257.2) 217.5 (178) 0.0067 0.4557 0.2393
IL-1, pg/mL 9.08 (1.6) 7.76 (2.6) 9.26 (11.1) 0.02 0.9318 0.0497
OP-1, ng/mL 54.49 (29.3) 81.79 (116.0) 167.1 (194.8) <0.0001 <0.0001 0.0013
LIF, pg/mL 228.5 (131.6) 107.5 (136.9) 128.4 (222.7) 0.0063 0.139 0.1991
Osteo, ng/mL 2.58 (6.6) 2.515 (4.9) 1.99 (3.9) 0.7437 0.893 0.5384
COMP, U/L 413.2 (339.9) 490.2 (207.5) 507.3 (352.9) 0.4652 0.3102 0.3865
aOA, osteoarthritis; RA, rheumatoid arthritis; IL, interleukin; OP-1, osteogenic protein 1; LIF, leukemia-inhibitory factor; Osteo, osteocalcin; COMP, cartilage oligomeric
protein. Absolute values of biomarkers detected in synovial fluid of patients with osteoarthritis, rheumatoid arthritis and asymptomatic organ donors. P values were
calculated by using an unpaired, two-tailed Mann-Whitney t-test with 95% confidence interval. Values are expressed as medians (interquartile ranges).
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correlations between IL-6 and IL-1, IL-6 and IL-8, osteo-
calcin and IL-1, osteocalcin and IL-11, and IL-8 and LIF
lost the level of significance. A moderate positive correla-
tion was detected between the SF WBC count and the
IL-1 and IL-6 concentrations (Spearman’s r = 0.4, P =
0.03; and Spearman’s r = 0.37, P = 0.005, respectively),
but no correlation was seen after the Bonferroni correc-
tion for multiple comparisons was applied. No correla-
tions were identified between WBC count and IL-8, IL-
11, LIF, OP-1, COMP or osteocalcin. No significant dif-
ferences were detected in tested biomarkers in OA
patients with active or inactive disease as defined by
WOMAC index score, and no correlation was found
between the biomarkers and the grade of radiological
damage defined by the K-L score.
Discussion
The usefulness of SF and/or serum-soluble biomarkers
in the assessment of treatment efficacy or for monitor-
ing disease progression in RA and OA remains contro-
versial. The goal of the present study was to
characterize and compare the concentrations of selected
biological mediators (both catabolic and anabolic) in the
SF obtained from RA or OA patients in comparison to
SF aspirated from the knee joints of asymptomatic
organ donors and to investigate whether any of these
molecules might have utility as prognostic markers.
Markers of catabolism included IL-1b and the IL-6
family of chemokines (IL-6, IL-8, IL-11 and LIF), which
have been shown in cartilage to negatively correlate
with OP-1 [12], the anabolic marker evaluated here. In
Table 3 Spearman’s rank correlation coefficients for RA study populationa
IL-1 IL-6 IL-8 IL-11 LIF Osteocalcin COMP OP-1
IL-1 1.0000
IL-6 r = 0.3643
P = 0.0801
1.0000
IL-8 r = 0.5174
P = 0.0096
r = 0.8643
P = 0.001
1.0000
IL-11 r = -0.2278
P = 0.2843
r = -0.1530
P = 0.4753
r = -0.0626
P = 0.7713
1.0000
LIF r = -0.1802
P = 0.3996
r = 0.2733
P = 0.1963
r = 0.3803
P = 0.0667
r = 0.2124
P = 0.3191
1.0000
Osteocalcin r = -0.0670
P = 0.7559
r = 0.1878
P = 0.3795
r = 0.1670
P = 0.4355
r = 0.3783
P = 0.0684
r = 0.5927
P = 0.0023
1.0000
COMP r = 0.3009
P = 0.1531
r = 0.0991
P = 0.6449
r = 0.0548
P = 0.7993
r = -0.2009
P = 0.3466
r = -0.3307
P = 0.1145
r = -0.0548
P = 0.7993
1.0000
OP-1 r = 0.5791
P = 0.0030
r = 0.2896
P = 0.1699
r = 0.4130
P = 0.0448
r = -0.1896
P = 0.3750
r = 0.1897
P = 0.3746
r = 0.1817
P = 0.3954
r = 0.1922
P = 0.3683
1.000
aRA, rheumatoid arthritis; IL, interleukin; LIF, leukemia-inhibitory factor; COMP, cartilage oligomeric protein; OP-1, osteogenic protein 1. Spearman’s rank
correlation coefficients (IL-1, IL-6, IL-8, IL-11, LIF, osteocalcin, COMP and OP-1) for the RA cohort are expressed as Spearman’s r and P values. A total of 22 RA
patients were sampled, five male and seventeen female.
Table 4 Spearman rank correlation coefficients for OA study populationa
IL-1 IL-6 IL-8 IL-11 LIF Osteocalcin COMP OP-1
IL-1 1.0000
IL-6 r = -0.3386
P = 0.186
1.0000
IL-8 r = 0.6233
P = 0.001
r = -0.3709
P = 0.0095
1.0000
IL-11 r = -0.2312
P = 0.1136
r = 0.5384
P = 0.0001
r = -0.2365
P = 0.1056
1.0000
LIF r = -0.5241
P = 0.0001
r = 0.7165
P = 0.001
r = -0.4012
P = 0.0047
r = 0.4352
P = 0.0020
1.0000
Osteocalcin r = -0.3432
P = 0.0169
r = 0.4538
P = 0.0012
r = -0.4456
P = 0.0015
r = 0.3094
P = 0.0324
r = 0.5043
P = 0.0003
1.0000
COMP r = 0.0807
P = 0.5856
r = 0.0294
P = 0.8427
r = -0.1522
P = 0.3018
r = 0.1623
P = 0.2704
r = -0.0854
P = 0.5639
r = 0.1526
P = 0.3004
1.0000
OP-1 r = 0.1038
P = 0.4828
r = 0.0730
P = 0.6222
r = -0.0529
P = 0.7211
r = 0.2028
P = 0.1669
r = 0.1003
P = 0.4975
r = 0.2084
P = 0.1552
r = 0.1193
P = 0.4193
1.000
a OA, osteoarthritis; IL, interleukin; LIF, leukemia-inhibitory factor; COMP, cartilage oligomeric protein; OP-1, osteogenic protein 1. Spearman’s rank correlation
coefficients (IL-1, IL-6, IL-8, IL-11, LIF, osteocalcin, COMP and OP-1) for the OA cohort are expressed as Spearman’s r and P values. A total of 45 OA patients were
sampled, six male and thirty-nine female.
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addition, COMP and osteocalcin were included as mar-
kers of matrix metabolism. Our results suggest that the
concentrations of the pathophysiologically important
biomarkers in SF are different between OA and RA and
depend on the mechanisms that drive cellular responses
in each disease. IL-11, LIF and OP-1 appear to be signif-
icant for OA processes, while IL-1, IL-6, IL-8 and OP-1
may play an important role in RA.
In line with other studies [17,18], our data also indicate
that RA, but not OA, is characterized by elevated IL-6
and IL-8 concentrations. The role of IL-6 in OA is
unclear, and there are conflicting findings in the litera-
ture that indicate both procatabolic [19,20] and anticata-
bolic effects of IL-6 in chondrocytes and synoviocytes
[21-23]. In contrast, the role of IL-6 in inflammatory pro-
cesses, including RA, appears to be more consistent and
involves promotion of the disease by stimulating B and T
cells [24,25]. Furthermore, the concentrations of IL-6 in
SF were shown to positively correlate with those in the
sera of patients with RA, OA, crystal deposition and
other forms of inflammatory arthritis [26]. As expected,
IL-6 concentrations in biological fluids of asymptomatic
organ donors were at the baseline concentrations and
were significantly lower than those in patients with RA
or OA. Similar to IL-6, IL-11 concentrations have been
found to be significantly higher in SF than in serum,
though the concentrations are highly correlated. In the
present study, IL-11 concentrations were 1.4-fold higher
in OA samples than those in asymptomatic organ donor
samples, but not higher than those in the RA group.
Trontzas et al. [27] reported that SF IL-11 concentrations
are higher in OA than in treated RA, but not in untreated
RA. As we did not distinguish treated from untreated RA,
we were not able to confirm this relationship. Although
elevated concentrations of IL-11 have been found in RA,
limited data are available on this cytokine [27]. Still, our
results suggest that further studies of the potential utility
of IL-11 as a biomarker are warranted.
LIF, a cytokine in the IL-6 family, is downregulated by
OP-1 and plays a role in bone formation and resorption.
It has not been well-studied as a potential biomarker,
and its association with OA has been based mainly on
gene expression studies in synoviocytes [28]. In the pre-
sent study, LIF concentrations were significantly lower
in both the OA and RA groups compared to the organ
donors. This finding differs from that in a previous
report that detected elevated SF LIF concentrations in
some patients with severe RA [29]. This discrepancy
may be attributed to an inhibitory effect of other cyto-
kines on LIF, for example, IL-4 [30]. Nonetheless, the
difference in LIF response in OA relative to the other
members of the IL-6 family (IL-8 and IL-11) suggests
that LIF is either involved at different stages of the dis-
eases or has a distinct function.
The cytokine that has received the most attention
among the arthritic diseases is IL-1b, yet as a biomarker,
it has been studied more in either experimental OA [31]
or SF of patients with RA [32]. In OA, it is primarily
viewed as a mediator of degenerative processes in
human joint tissues [33-36], and substantial knowledge
has been accumulated regarding its expression in carti-
lage and synovium, the mechanisms of its activation and
interactions, its signaling, its regulation of and relation-
ship with other active molecules, and so on. IL-1b,
together with IL-6, has been shown in OA synovium to
contribute to the progression of the disease by enhan-
cing the susceptibility of chondrocytes to stimulation
with proanabolic mediators [37]. In posttraumatic OA,
especially in acute phase responses, IL-1b together with
tumor necrosis factor a and IL-6 are well-established
regulators of cartilage degradation and resorption [1].
As anticipated, in the current study, IL-1b and IL-6 con-
centrations were greater in RA patients than in OA
patients or asymptomatic organ donors. However, to
our surprise, the concentrations of IL-1b in SF of
asymptomatic organ donors were statistically higher
than those in OA, suggesting that IL-1b is involved only
during the acute phase of the disease or is needed to
initiate or trigger catabolic events. It is also a possibility
that OA patients enrolled in our study underwent phar-
macological treatment that had an inhibitory effect on
IL-1b production or that only a subpopulation of
patients with OA may have elevated IL-1b. The latter
hypothesis is supported by a recent publication by Neu
et al. [38], who reported elevated concentrations of IL-
1b in only a few OA samples, while in other samples
IL-1b either was barely detectable or was below the
detection limit. Though in previous publications IL-1b
and IL-6 have been shown to be predictive of either OA
or RA, our data indicate a closer association of both
cytokines with RA than with OA.
As markers of matrix metabolism, we used COMP
and osteocalcin. COMP is an extracellular glycoprotein
and is a member of the thrombospondin family of cal-
cium-binding proteins. COMP is associated with carti-
lage breakdown and has been studied as a potential
diagnostic and prognostic indicator as well as a marker
of disease severity or the efficacy of treatment (reviewed
in [39]). It has been reported that COMP concentrations
in SF are 10 times higher than in serum and that higher
COMP concentrations have been observed in patients
with higher radiographic Kellgren-Lawrence grades.
However, despite these expectations, here we were not
able to identify an association of COMP concentrations
with the type of disease or its severity, perhaps because
of the limitations of our study. Samples were collected
at only one time point rather than longitudinally, there
was a lack of untreated controls and/or the sample size
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of each group was not large enough. As with COMP, we
did not find differences in osteocalcin concentrations
between the experimental groups, though elevation of
osteocalcin has been detected previously in the destruc-
tive form of OA in comparison with nondestructive OA
[40]. In agreement with our data, the observations of
Salisbury et al. [41] suggested that in a predominantly
older female population, the rate of normal bone turn-
over measured by osteocalcin in donors was not signifi-
cantly different from that of OA or RA patients.
Furthermore, it has been reported that OA and RA
patients treated with nonsteroidal anti-inflammatory
drugs showed significantly lower concentrations of SF
osteocalcin than patients treated with glucocorticoids
[42]. Conflicting data on both COMP and osteocalcin
indicate that only carefully designed longitudinal studies
with well-controlled, large patient cohorts may shed the
light on their potential as biomarkers.
Previously, we described in detail OP-1/BMP-7 in SF
from organ donors or OA and RA patients [9]. In this
study, it was used primarily for correlation with other
catabolic markers or because there are fewer anabolic
than catabolic biomarkers, where OP-1/BMP-7 definitely
belongs to the former category. As earlier, we confirmed
the elevated concentrations of OP-1/BMP-7 released
into the SF of RA patients in comparison to OA patients
and organ donors. A higher quantity of OP-1/BMP-7 in
samples characterized by higher concentrations of proin-
flammatory mediators may not necessarily indicate a
higher synthesis of this growth factor. Our unpublished
data suggest that treatment with IL-1b, for example,
induce activation of pro-OP-1 and thus release of active
OP-1 from the matrix. In addition, catabolic mediators
lead to matrix loosening/degradation, which also may
favor activation and/or release of the growth factor that
has been trapped within the matrix or bound to the
extracellular binding proteins or matrix components as
it occurs with the transforming growth factor b latency
protein [43].
Biomarkers were also assessed on the basis of the
activity of the disease within each patient cohort. OA
was assessed on the basis of the WOMAC index score,
and RA was evaluated on the basis of the synovial WBC
count, ESR and CRP level. Though no significant differ-
ences between biomarkers and disease activity were
found, there was a trend toward an elevation of proin-
flammatory mediators in the active state of OA or RA.
Conclusions
In conclusion, the results of this study point to the
mechanism-specific activation of biomarkers, where RA
associated with higher inflammatory components is
characterized by a profile of elevated IL-1, IL-6, IL-8
and OP-1 as well as low concentrations of LIF. On the
basis of our studies, the OA profile of biomarkers could
be described as elevated concentrations of IL-11 and
OP-1 and low concentrations of LIF. To move forward
in the field of biomarkers, the criteria for study design
should be more stringent and should include larger,
well-defined patient cohorts, preferably without any
accompanying therapeutic interventions that obscure
the accuracy of analysis.
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